Moderna shares dropped sharply Thursday morning after the COVID-19 vaccine maker announced plans to scale back its research and development (R&D) efforts in a bid to reduce costs. The company will now concentrate on securing FDA approval for 10 key products, including vaccines for respiratory syncytial virus (RSV), cancer treatments, and a combination COVID-19 and…
